Mikrobiota jelitowa a leki. Interakcje wpływające na skuteczność i bezpieczeństwo farmakoterapii

Joanna Nycz; Alicja Zajdel

doi:10.2478/ahem-2021-0009

.blurhash-client-img { display: none !important; }

Mikrobiota jelitowa a leki. Interakcje wpływające na skuteczność i bezpieczeństwo farmakoterapii

Postępy Higieny i Medycyny Doświadczalnej

Volume 75 (2021): Issue 1 (January 2021)

By: Joanna Nycz and Alicja Zajdel

Open Access

|Dec 2021

Abstract

The intestinal microbiota is an integral part of the body that enables its proper functioning. Owing to intestinal microorganisms it is possible to stimulate the immune system, synthesize vitamins and improve the absorption of nutrients. However, its activity may also have adverse effects on the body, resulting e.g. from the processing of the intestinal contents. The microbiota-drug interaction described in this article is based on the positive and negative effects of intestinal microorganisms on pharmacotherapy by directly and indirectly influencing the fate of the drug in the body. Due to the fact that the microbiome is an inseparable element of the body, interfering with even a small part of it can lead to farreaching, sometimes unexpected effects. Hence, in order to improve the efficacy and safety of pharmacotherapy, it is necessary to explain the mechanisms of microbiota's influence on the fate of the drug in the body.

The article summarizes the current knowledge on the biological activity of the intestinal microbiota, in particular on the interactions of microbiota and drugs that determine the effectiveness and safety of pharmacotherapy. A search was performed in September 2020 in the databases Pubmed, Scopus, Web of Science, Cochrane Library, and gray literature using the terms: “gut microbiota”, “microbiome”, “drug metabolism”, “gut microbiota-drug interactions”. The article discusses the interactions between the microbiota and drugs, including the group of antibiotics, proton pump inhibitors, sulfonamides, 5-aminosalicylic acid derivatives, non-steroidal anti-inflammatory drugs, anti-cancer drugs, statins or metformin.

References

Zimmermann M., Zimmermann-Kogadeeva M., Wegmann R., Goodman A.L.: Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature, 2019; 570: 462-467
Open DOI Search in Google Scholar Back to article
Turnbaugh P.J., Ley R.E., Hamady M., Fraser-Liggett C.M., Knight R., Gordon J.I.: The human microbiome project. Nature, 2007; 449: 804-810
Open DOI Search in Google Scholar Back to article
Swanson H.I.: Drug metabolism by the host and gut microbiota: A partnership or rivalry? Drug Metab. Dispos., 2015; 43: 1499-1504
Open DOI Search in Google Scholar Back to article
Wilson I.D., Nicholson J.K.: Gut microbiome interactions with drug metabolism, efficacy, and toxicity. Transl. Res., 2017; 179: 204222
Open DOI Search in Google Scholar Back to article
Franzosa E.A., Huang K., Meadow J.F., Gevers D., Lemon K.P., Bohannan B.J., Huttenhower C.: Identifying personal microbiomes using metagenomic codes. Proc. Natl. Acad. Sci. USA, 2015; 112: E2930-E2938
Open DOI Search in Google Scholar Back to article
Baker J.M., Al-Nakkash L., Herbst-Kralovetz M.M.: Estrogen-gut microbiome axis: Physiological and clinical implications. Maturitas, 2017; 103: 45-53
Open DOI Search in Google Scholar Back to article
Conlon M.A., Bird A.R.: The impact of diet and lifestyle on gut microbiota and human health. Nutrients, 2015; 7: 17-44
Open DOI Search in Google Scholar Back to article
Crovesy L., Masterson D., Rosado E.L.: Profile of the gut microbiota of adults with obesity: A systematic review. Eur. J. Clin. Nutr., 2020; 74, 1251-1262
Open DOI Search in Google Scholar Back to article
Hopkins M.J., Sharp R., Macfarlane G.T.: Variation in human intestinal microbiota with age. Dig. Liver Dis., 2002; 34: S12-S18
Open DOI Search in Google Scholar Back to article
Claesson M.J., Jeffery I.B., Conde S., Power S.E., O’Connor E.M., Cusack S., Harris H.M., Coakley M., Lakshminarayanan B., O’Sullivan O. i wsp.: Gut microbiota composition correlates with diet and health in the elderly. Nature, 2012; 488: 178-184
Open DOI Search in Google Scholar Back to article
Clark R.I. Walker D.W.: Role of gut microbiota in aging-related health decline: Insights from invertebrate models. Cell Mol. Life Sci., 2018; 75: 93-101
Open DOI Search in Google Scholar Back to article
Clarke G., O’Mahony S.M., Dinan T.G., Cryan J.F.: Priming for health: Gut microbiota acquired in early life regulates physiology, brain and behaviour. Acta Paediatr., 2014; 103: 812-819
Open DOI Search in Google Scholar Back to article
Dogra S., Sakwinska O., Soh S.E., Ngom-Bru C., Brück W.M., Berger B., Brüssow H., Lee Y.S., Yap F., Chong Y.S. i wsp.: Dynamics of infant gut microbiota are influenced by delivery mode and gestational duration and are associated with subsequent adiposity. mBio, 2015; 6: e02419-14
Open DOI Search in Google Scholar Back to article
Brinkworth G.D., Noakes M., Clifton P.M., Bird A.R.: Comparative effects of very low-carbohydrate, high-fat and high-carbohydrate, low-fat weight-loss diets on bowel habit and faecal short-chain fatty acids and bacterial populations. Br. J. Nutr., 2009; 101: 14931502
Open DOI Search in Google Scholar Back to article
Ticinesi A., Milani C., Lauretani F., Nouvenne A., Mancabelli L., Lugli G.A., Turroni F., Duranti S., Mangifesta M., Viappiani A. i wsp.: Gut microbiota composition is associated with polypharmacy in elderly hospitalized patients. Sci. Rep., 2017; 7: 11102
Open DOI Search in Google Scholar Back to article
Stokholm J., Thorsen J., Blaser M.J., Rasmussen M.A., Hjelmsø M., Shah S., Christensen E.D., Chawes B.L., Bønnelykke K., Brix S. i wsp.: Delivery mode and gut microbial changes correlate with an increased risk of childhood asthma. Sci. Transl. Med., 2020; 12: eaax9929
Open DOI Search in Google Scholar Back to article
Tropini C., Earle K.A., Huang K.C., Sonnenburg J.L.: The gut microbiome: Connecting spatial organization to function. Cell Host Microbe, 2017; 21: 433-442
Open DOI Search in Google Scholar Back to article
Cheng Y., Jin U.H., Allred C.D., Jayaraman A., Chapkin R.S., Safe S.: Aryl hydrocarbon receptor activity of tryptophan metabolites in young adult mouse colonocytes. Drug Metab. Dispos., 2015; 43: 1536-1543
Open DOI Search in Google Scholar Back to article
Zelante T., Iannitti R,G., Cunha C., De Luca A., Giovannini G., Pieraccini G., Zecchi R., D’Angelo C., Massi-Benedetti C., Fallarino F.: Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity, 2013; 39: 372-385
Open DOI Search in Google Scholar Back to article
Maranduba C.M., De Castro S.B., de Souza G.T., Rossato C., da Guia F.C., Valente M.A., Rettore J.V., Maranduba C.P., de Souza C.M., do Carmo A.M. i wsp.: Intestinal microbiota as modulators of the immune system and neuroimmune system: Impact on the host health and homeostasis. J. Immunol. Res., 2015; 2015: 931574
Open DOI Search in Google Scholar Back to article
Björkholm B., Bok C.M., Lundin A., Rafter J., Hibberd M.L., Pettersson S.: Intestinal microbiota regulate xenobiotic metabolism in the liver. PLoS One, 2009; 4: e6958
Open DOI Search in Google Scholar Back to article
Kaur H., Bose C., Mande S.S.: Tryptophan metabolism by gut microbiome and gut-brain-axis: An in silico analysis. Front. Neurosci., 2019; 13: 1365
Open DOI Search in Google Scholar Back to article
Ridaura V., Belkaid Y.: Gut microbiota: The link to your second brain. Cell, 2015; 161: 193-194
Open DOI Search in Google Scholar Back to article
Reigstad C.S., Salmonson C.E., Rainey J.F.3rd, Szurszewski J.H., Linden D.R., Sonnenburg J.L., Farrugia G., Kashyap P.C.: Gut microbes promote colonic serotonin production through an effect of short-chain fatty acids on enterochromaffin cells. FASEB J., 2015; 29: 1395-1403
Open DOI Search in Google Scholar Back to article
Vecsey C.G., Hawk J.D., Lattal K.M., Stein J.M., Fabian S.A., Attner M.A., Cabrera S.M., McDonough C.B., Brindle P.K., Abel T., Wood M.A.: Histone deacetylase inhibitors enhance memory and synaptic plasticity via CREB:CBP-dependent transcriptional activation. J. Neurosci. 2007; 27: 6128-6140
Open DOI Search in Google Scholar Back to article
Hoyles L., Snelling T., Umlai U.K., Nicholson J.K., Carding S.R., Glen R.C., McArthur S.: Microbiome-host systems interactions: Protective effects of propionate upon the blood-brain barrier. Microbiome, 2018; 6: 55
Open DOI Search in Google Scholar Back to article
Kelly J.R., Kennedy P.J., Cryan J.F., Dinan T.G., Clarke G., Hyland N.P.: Breaking down the barriers: The gut microbiome, intestinal permeability and stress-related psychiatric disorders. Front. Cell. Neurosci., 2015; 9: 392
Open DOI Search in Google Scholar Back to article
Baothman O.A., Zamzami M.A., Taher I., Abubaker J., Abu-Farha M.: The role of gut microbiota in the development of obesity and diabetes. Lipids Health Dis., 2016; 15: 108
Open DOI Search in Google Scholar Back to article
Becker C., Neurath M.F., Wirtz S.: The intestinal microbiota in inflammatory bowel disease. ILAR J., 2015; 56: 192-204
Open DOI Search in Google Scholar Back to article
Dahmus J.D., Kotler D.L., Kastenberg D.M., Kistler C.A.: The gut microbiome and colorectal cancer: A review of bacterial pathogenesis. J. Gastrointest. Oncol., 2018; 9: 769-777
Open DOI Search in Google Scholar Back to article
Kaur H., Das C., Mande S.S.: In silico analysis of putrefaction pathways in bacteria and its implication in colorectal cancer. Front. Microbiol., 2017; 8: 2166
Open DOI Search in Google Scholar Back to article
Hughes R., Magee E.A., Bingham S.: Protein degradation in the large intestine: Relevance to colorectal cancer. Curr. Issues Intest. Microbiol., 2000; 1: 51-58
Search in Google Scholar Back to article
Toden S., Bird A.R., Topping D.L., Conlon M.A.: Resistant starch attenuates colonic DNA damage induced by higher dietary protein in rats. Nutr. Cancer, 2005; 51: 45-51
Open DOI Search in Google Scholar Back to article
Shen W., Gaskins H.R., McIntosh M.K.: Influence of dietary fat on intestinal microbes, inflammation, barrier function and metabolic outcomes. J. Nutr. Biochem., 2014; 25: 270-280
Open DOI Search in Google Scholar Back to article
Nakamura J., Kubota Y., Miyaoka M., Saitoh T., Mizuno F, Benno Y.: Comparison of four microbial enzymes in Clostridia and Bacteroides isolated from human feces. Microbiol. Immunol., 2002; 46: 487-490
Open DOI Search in Google Scholar Back to article
Pollet R.M., D’Agostino E.H., Walton W.G., Xu Y., Little M.S., Biernat K.A., Pellock S.J., Patterson L.M., Creekmore B.C., Isenberg H.N., i wsp.: An atlas of β-glucuronidases in the human intestinal microbiome. Structure, 2017; 25: 967-977
Open DOI Search in Google Scholar Back to article
Vila A.V., Collij V., Sanna S., Sinha T., Imhann F., Bourgonje A.R., Mujagic Z., Jonkers D.M., Masclee A.A., Fu J. i wsp.: Impact of commonly used drugs on the composition and metabolic function of the gut microbiota. Nat. Commun., 2020; 11: 362
Open DOI Search in Google Scholar Back to article
Finlayson-Trick E.C., Fischer J.A., Goldfarb D.M., Karakochuk C.D.: The effects of iron supplementation and fortification on the gut microbiota: A review. Gastrointest. Disord., 2020; 2: 327-340
Open DOI Search in Google Scholar Back to article
Skonieczna-Żydecka K., Łoniewski I., Misera A., Stachowska E., Maciejewska D., Marlicz W., Galling B.: Second-generation antipsychotics and metabolism alterations: A systematic review of the role of the gut microbiome. Psychopharmacology, 2019; 236: 1491-1512
Open DOI Search in Google Scholar Back to article
Zhang S., Chen D.C.: Facing a new challenge: The adverse effects of antibiotics on gut microbiota and host immunity. Chin. Med. J., 2019; 132: 1135-1138
Open DOI Search in Google Scholar Back to article
Ponziani F.R., Zocco M.A., D’Aversa F., Pompili M., Gasbarrini A.: Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation. World J. Gastroenterol., 2017; 23: 4491-4499
Open DOI Search in Google Scholar Back to article
Imhann F., Bonder M.J., Vila A.V., Fu J., Mujagic Z., Vork L., Tigchelaar E.F., Jankipersadsing S.A., Cenit M.C., Harmsen H.J. i wsp.: Proton pump inhibitors affect the gut microbiome. Gut, 2016; 65: 740-748
Open DOI Search in Google Scholar Back to article
Jackson M.A., Goodrich J.K., Maxan M-E., Freedberg D.E., Abrams J.A., Poole A.C., Sutter J.L., Welter D., Ley R.E., Bell J.T. i wsp.: Proton pump inhibitors alter the composition of the gut microbiota. Gut, 2016; 65: 749-756
Open DOI Search in Google Scholar Back to article
Moayyedi P., Eikelboom J.W., Bosch J., Connolly S.J., Dyal L., Shestakovska O., Leong D., Anand S.S., Störk S., Branch K.R. i wsp.: Safety of proton pump inhibitors based on a large, multiyear, randomized trial of patients receiving rivaroxaban or aspirin. Gastroenterology, 2019; 157: 682-691
Open DOI Search in Google Scholar Back to article
Yepuri G., Sukhovershin R., Nazari-Shafti T.Z., Petrascheck M., Ghebre Y.T., Cooke J.P.: Proton pump inhibitors accelerate endothelial senescence. Circ. Res., 2016; 118: e36-e42
Open DOI Search in Google Scholar Back to article
Forslund K., Hildebrand F., Nielsen T., Falony G., Le Chatelier E., Sunagawa S., Prifti E., Vieira-Silva S., Gudmundsdottir V., Krogh Pedersen H. i wsp.: Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature, 2015; 528: 262-266
Open DOI Search in Google Scholar Back to article
Wu H., Esteve E., Tremaroli V., Khan M.T., Caesar R., Mannerås-Holm L., Ståhlman M., Olsson L.M., Serino M., Planas- Fèlix M. i wsp.: Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat. Med., 2017; 23: 850-858
Open DOI Search in Google Scholar Back to article
Vieira-Silva S., Falony G., Belda E., Nielsen T., Aron-Wisnewsky J., Chakaroun R., Forslund S., Assmann K., Valles-Colomer M., Nguyen T.T. i wsp.: Statin therapy is associated with lower prevalence of gut microbiota dysbiosis. Nature, 2020; 581: 310-315
Open DOI Search in Google Scholar Back to article
Noh K., Kang Y.R., Nepal M.R., Shakya R., Kang M.J., Kang W., Lee S., Jeong H.G., Jeong T.C.: Impact of gut microbiota on drug metabolism: An update for safe and effective use of drugs. Arch. Pharm. Res., 2017; 40: 1345-1355
Open DOI Search in Google Scholar Back to article
Lauschke V.M., Ingelman-Sundberg M.: Prediction of drug response and adverse drug reactions: From twin studies to Next Generation Sequencing. Eur. J. Pharm. Sci., 2019; 130: 65-77
Open DOI Search in Google Scholar Back to article
Sharma A., Buschmann M.M., Gilbert J.A.: Pharmacomicrobiomics: The holy grail to variability in drug response? Clin. Pharmacol. Ther., 2019; 106: 317-328
Open DOI Search in Google Scholar Back to article
Claesson M.J., Clooney A.G., O’Toole P.W.: A clinician’s guide to microbiome analysis. Nat. Rev. Gastroenterol. Hepatol., 2017; 14: 585-595
Open DOI Search in Google Scholar Back to article
Davenport E.R., Sanders J.G., Song S.J., Amato K.R., Clark A.G., Knight R.: The human microbiome in evolution. BMC Biol., 2017; 15: 127
Open DOI Search in Google Scholar Back to article
Arkhipova O.V., Akimenko V.K.: Unsaturated organic acids as terminal electron acceptors for reductase chains of anaerobic bacteria. Mikrobiologiia, 2005; 74: 725-737
Open DOI Search in Google Scholar Back to article
Koppel N., Rekdal V.M., Balskus E.P.: Chemical transformation of xenobiotics by the human gut microbiota. Science, 2017; 356: 1246-1257
Open DOI Search in Google Scholar Back to article
Clarke G., Sandhu K.V., Griffin B.T., Dinan T.G., Cryan J.F., Hyland N.P.: Gut reactions: Breaking down xenobiotic-microbiome interactions. Pharmacol. Rev., 2019; 71: 198-224
Open DOI Search in Google Scholar Back to article
Gopalakrishnan V., Spencer C.N., Nezi L., Reuben A., Andrews M.C., Karpinets T.V., Prieto P.A., Vicente D., Hoffman K., Wei S.C. i wsp.: Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science, 2018; 359: 97-103
Open DOI Search in Google Scholar Back to article
Routy B., Le Chatelier E., Derosa L., Duong C.P., Alou M.T., Daillère R., Fluckiger A., Messaoudene M., Rauber C., Roberti M.P. i wsp.: Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science, 2018; 359: 91-97
Open DOI Search in Google Scholar Back to article
Hubbard T.D., Murray I.A., Perdew G.H.: Indole and tryptophan metabolism: Endogenous and dietary routes to Ah receptor activation. Drug Metab. Dispos., 2015; 43: 1522-1535
Open DOI Search in Google Scholar Back to article
Jin U.H., Lee S.O., Sridharan G., Lee K., Davidson L.A., Jayaraman A., Chapkin R.S., Alaniz R., Safe S.: Microbiome-derived tryptophan metabolites and their aryl hydrocarbon receptor-dependent agonist and antagonist activities. Mol. Pharmacol., 2014; 85: 777-788
Open DOI Search in Google Scholar Back to article
Venkatesh M., Mukherjee S., Wang H., Li H., Sun K., Benechet A.P., Qiu Z., Maher L., Redinbo M.R., Phillips R.S. i wsp.: Symbiotic bacterial metabolites regulate gastrointestinal barrier function via the xenobiotic sensor PXR and Toll-like receptor 4. Immunity, 2014; 41: 296-310
Open DOI Search in Google Scholar Back to article
Wallace B.D., Redinbo M.R.: Xenobiotic-sensing nuclear receptors involved in drug metabolism: A structural perspective. Drug Metab. Rev., 2013; 45: 79-100
Open DOI Search in Google Scholar Back to article
Lee S.H., An J.H., Lee H.J., Jung B.H.: Evaluation of pharmacokinetic differences of acetaminophen in pseudo germ-free rats. Biopharm. Drug Dispos., 2012; 33: 292-303
Open DOI Search in Google Scholar Back to article
Li H., He J., Jia W.: The influence of gut microbiota on drug metabolism and toxicity. Expert Opin. Drug. Metab. Toxicol., 2016; 12: 31-40
Open DOI Search in Google Scholar Back to article
Possamai L.A., McPhail M.J., Khamri W., Wu B., Concas D., Harrison M., Williams R., Cox R.D., Cox I.J., Anstee Q.M., Thursz M.R.: The role of intestinal microbiota in murine models of acetaminophen-induced hepatotoxicity. Liver Int., 2015; 35: 764-773
Open DOI Search in Google Scholar Back to article
Sousa T., Yadav V., Zann V., Borde A., Abrahamsson B., Basit A.W.: On the colonic bacterial metabolism of azo-bonded prodrugs of 5-aminosalicylic acid. J. Pharm. Sci., 2014; 103: 3171-3175
Open DOI Search in Google Scholar Back to article
Deloménie C., Fouix S., Longuemaux S., Brahimi N., Bizet C., Picard B., Denamur E., Dupret J.M.: Identification and functional characterization of arylamine N-acetyltransferases in eubacteria: Evidence for highly selective acetylation of 5-aminosalicylic acid. J. Bacteriol., 2001; 183: 3417-3427
Open DOI Search in Google Scholar Back to article
Kaddurah-Daouk R., Baillie R.A., Zhu H., Zeng Z.B., Wiest M.M, Nguyen U.T., Wojnoonski K., Watkins S.M, Trupp M., Krauss R.M.: Enteric microbiome metabolites correlate with response to simvastatin treatment. PLoS One, 2011; 6: e 25482
Open DOI Search in Google Scholar Back to article
Yoo D.H., Kim I.S., Van Le T.K., Jung I.H., Yoo H.H., Kim D.H.: Gut microbiota-mediated drug interactions between lovastatin and antibiotics. Drug Metab. Dispos., 2014; 42: 1508-1513
Open DOI Search in Google Scholar Back to article
Viaud S., Flament C., Zoubir M., Pautier P., LeCesne A., Ribrag V., Soria J.C., Marty V., Vielh P., Robert C. i wsp.: Cyclophosphamide induces differentiation of Th17 cells in cancer patients. Cancer Res. 2011; 71: 661-665
Open DOI Search in Google Scholar Back to article
Viaud S., Saccheri F., Mignot G., Yamazaki T., Daillère R., Hannani D., Enot D.P., Pfirschke C., Engblom C., Pittet M.J. i wsp.: The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science, 2013; 342: 971-976
Open DOI Search in Google Scholar Back to article
Roberts A.B., Wallace B.D., Venkatesh M.K., Mani S., Redinbo M.R.: Molecular insights into microbial β-glucuronidase inhibition to abrogate CPT-11 toxicity. Mol. Pharmacol., 2013; 84: 208-217
Open DOI Search in Google Scholar Back to article
Saitta K.S., Zhang C., Lee K.K., Fujimoto K., Redinbo M.R., Boelsterli U.A.: Bacterial β-glucuronidase inhibition protects mice against enteropathy induced by indomethacin, ketoprofen or diclofenac: Mode of action and pharmacokinetics. Xenobiotica, 2014; 44: 28-35
Open DOI Search in Google Scholar Back to article
Choi M.S., Yu J.S., Yoo H.H., Kim D.H.: The role of gut microbiota in the pharmacokinetics of antihypertensive drugs. Pharmacol. Res., 2018; 130: 164-171
Open DOI Search in Google Scholar Back to article
Haiser H.J., Gootenberg D.B., Chatman K., Sirasani G., Balskus E.P., Turnbaugh P.J.: Predicting and manipulating cardiac drug inactivation by the human gut bacterium Eggerthella lenta. Science, 2013; 341: 295-298
Open DOI Search in Google Scholar Back to article
Haiser H.J., Seim K.L., Balskus E.P., Turnbaugh P.J.: Mechanistic insight into digoxin inactivation by Eggerthella lenta augments our understanding of its pharmacokinetics. Gut Microbes, 2014; 5: 233-238
Open DOI Search in Google Scholar Back to article
Kumar K., Jaiswal S.K., Dhoke G.V., Srivastava G.N., Sharma A.K., Sharma V.K.: Mechanistic and structural insight into promiscuity based metabolism of cardiac drug digoxin by gut microbial enzyme. J. Cell. Biochem., 2018; 119: 5287-5296
Open DOI Search in Google Scholar Back to article
Hashim H., Azmin S., Razlan H., Yahya N.W., Tan H.J., Manaf M.R., Ibrahim N.M.: Eradication of Helicobacter pylori infection improves levodopa action, clinical symptoms and quality of life in patients with Parkinson’s disease. PLoS One, 2014; 9: e112330
Open DOI Search in Google Scholar Back to article
Matuskova Z., Anzenbacher P., Vecera R., Siller M., TlaskalovaHogenova H., Strojil J., Anzenbacherova E.: Effect of Lactobacillus casei on the pharmacokinetics of amiodarone in male Wistar rats. Eur. J. Drug Metab. Pharmacokinet., 2017; 42: 29-36
Open DOI Search in Google Scholar Back to article
Nakayama H., Kinouchi T., Kataoka K., Akimoto S., Matsuda Y., Ohnishi Y.: Intestinal anaerobic bacteria hydrolyse sorivudine, producing the high blood concentration of 5-(E)-(2-bromovinyl)uracil that increases the level and toxicity of 5-fluorouracil. Pharmacogenetics, 1997; 7: 35-43
Open DOI Search in Google Scholar Back to article
Okuda H., Ogura K., Kato A., Takubo H., Watabe T.: A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. J. Pharmacol. Exp. Ther., 1998; 287: 791-799
Search in Google Scholar Back to article
Poteres E., Hubert N., Poludasu S., Brigando G., Moore J., Keeler K., Isabelli A., Ibay I.C., Alt L., Pytynia M. i wsp.: Selective regional alteration of the gut microbiota by diet and antibiotics. Front. Physiol., 2020; 11: 797
Open DOI Search in Google Scholar Back to article
Stojančević M., Bojić G., Salami H.A., Mikov M.: The influence of intestinal tract and probiotics on the fate of orally administered drugs. Curr. Issues Mol. Biol., 2014; 16: 55-68
Search in Google Scholar Back to article
Zeevi D., Korem T., Zmora N., Israeli D., Rothschild D., Weinberger A., Ben-Yacov O., Lador D., Avnit-Sagi T., Lotan-Pompan M. i wsp.: Personalized nutrition by prediction of glycemic responses. Cell, 2015; 163: 1079-1094
Open DOI Search in Google Scholar Back to article
Wallace B.D., Roberts A.B., Pollet R.M., Ingle J.D., Biernat K.A., Pellock S.J., Venkatesh M.K., Guthrie L., O’Neal S.K., Robinson S.J. i wsp.: Structure and inhibition of microbiome β-glucuronidases essential to the alleviation of cancer drug toxicity. Chem. Biol., 2015; 22: 1238-1249
Open DOI Search in Google Scholar Back to article

Articles in this issue

DOI: https://doi.org/10.2478/ahem-2021-0009 | Journal eISSN: 1732-2693

Journal RSS Feed

Language: English, Polish

Page range: 762 - 772

Submitted on: Sep 16, 2020

Accepted on: Apr 8, 2021

Published on: Dec 7, 2021

Published by: Hirszfeld Institute of Immunology and Experimental Therapy

In partnership with: Paradigm Publishing Services

Publication frequency: 1 issue per year

Keywords:

gut microbiota,

drug metabolism,

gut microbiota-drug interactions

Related subjects:

Life sciences,

Molecular biology,

Microbiology and virology,

Medicine,

Basic medical science,

Immunology

© 2021 Joanna Nycz, Alicja Zajdel, published by Hirszfeld Institute of Immunology and Experimental Therapy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Volume 75 (2021): Issue 1 (January 2021)